Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Mesothelioma

Trial Information

Axitinib in Malignant Mesothelioma

Official Title: A Randomized Phase I/II Study of Standard Chemotherapy (Cisplatin and Pemetrexed) With or Without Axitinib in Patients With Malignant Mesothelioma: Interim Biopsy Analysis to Determine Efficacy

Summary

The purpose of this study is to investigate the effects of axitinib, a potent angiogenesis inhibitor, on tissue and clinical outcome in combination with chemotherapy given to patients with mesothelioma

Phase: Phase 1/Phase 2

Sponsor: The Netherlands Cancer Institute

Overall Contacts:

P. Baas, Dr.
+31 (0)20-5122958

W. A. Buikhuisen, MD
Phone: +31 (0)20-5122958

Locations (1)

Country State City Zip Facility and Contact
Netherlands Noord-Holland Amsterdam 1066 CX Antoni van Leeuwenhoekziekenhuis (NKI-AVL)
P Baas, Dr.
+31 (0)20-5122958
p.baas@nki.nl

P Baas, Dr.
Principal Investigator

NCT ID:NCT01211275

Date Last Changed: September 28, 2010